On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Photography is a lifeline for member, veteran
- Local 94 Leads by Example
- Truth and Lies about the BNSF Crew Consist Agreement
- Less Than One Week Left to Book a Room for the Denver Regional Training Seminar!
- Monopoly in the Making: Union Pacific’s Merger Ambitions Could Shake UP the Rail Industry
- Celebrating the Life and Legacy of Brother Daniel A. May
- Championing Rail and Transit Safety from Coast to Coast
- Potential NJ Transit Strike: What SMART-TD Members Need to Know
- Union Support Available for Members Affected by Maryland, Virginia, and Pennsylvania Flooding
- Local 202’s Tierney Gallegos connects union strength with public good